基根金良可以通过TLR4/NF-κB/NLRP3通路改善阿尔茨海默病
Bin Zhang1, Liudan Chen1, Mengru Kang1
1Department of Traditional Chinese Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sun University, Guangzhou, Guangdong 510120, China.
Tissue & cell
|March 8, 2025
概括
格根金莲 (GGQLD) 改善了老鼠的阿尔茨海默病 (AD) 通过减少大脑损伤和炎症. 这种传统中医药调节了热的途径,为AD提供了潜在的治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,导致痴呆,有效治疗方法有限.
- 子 (Gegen Qinlian Decoction,GGQLD) 是一种中国传统医药,具有潜在的治疗特性.
研究的目的:
- 评估GGQLD对阿尔茨海默病 (AD) 的治疗效果.
- 为了研究GGQLD在AD治疗中的潜在分子机制.
主要方法:
- 网络药理学和生物信息学确定了376种GGQLD活性成分和427种药物标,揭示了与AD交叉的7个关键标.
- 功能性丰富性分析表明,GGQLD调节了与热死相关的途径.
- 在体内研究中使用AD大鼠模型来评估GGQLD对认知功能和大脑病理的影响.
主要成果:
- 在AD大鼠中,GGQLD的使用显著改善了空间学习和记忆,减少了延迟时间和增加了平台交叉.
- GGQLD治疗减少了海马组织损伤和异常的粉样β (Aβ) 沉积.
- 在机械上,GGQLD降低了关键的与热核死相关的标 (TLR4,NF-κB,NLRP3,IL-1β,Caspase-1) 和调节的通路,包括NOD类受体和NF-kappa B信号传递.
结论:
- GGQLD在阿尔茨海默病 (AD) 中显示出显著的治疗潜力.
- GGQLD通过调节热亡途径来缓解认知缺陷和神经炎症.
- 这项研究为GGQLD作为AD的新型治疗剂提供了科学基础.
更多相关视频
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
618
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142
Alzheimer's Disease: Overview
412
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
412
